Sholl Lynette M, Longtine Janina, Kuo Frank C
Brigham and Women's Hospital, Boston, Massachusetts.
Yale University, New Haven, Connecticut.
Curr Protoc Hum Genet. 2017 Jan 11;92:10.4.1-10.4.49. doi: 10.1002/cphg.31.
A subset of acute leukemias and other myeloid neoplasms contains specific genetic alterations, many of which are associated with unique clinical and pathologic features. These alterations include chromosomal rearrangements leading to oncogenic fusion proteins or alteration of gene expression by juxtaposing oncogenes to enhancer elements, as well as mutations leading to aberrant activation of a variety of proteins critical to hematopoietic progenitor cell proliferation and differentiation. Molecular analysis is central to diagnosis and clinical management of leukemias, permitting genetic confirmation of a clinical and histologic impression, providing prognostic and predictive information, and facilitating detection of minimal residual disease. This unit will outline approaches to the molecular diagnosis of the most frequent and clinically relevant genetic alterations in acute leukemias and myeloid neoplasms. © 2017 by John Wiley & Sons, Inc.
一部分急性白血病和其他髓系肿瘤含有特定的基因改变,其中许多与独特的临床和病理特征相关。这些改变包括导致致癌融合蛋白的染色体重排,或通过将癌基因与增强子元件并列而改变基因表达,以及导致对造血祖细胞增殖和分化至关重要的多种蛋白质异常激活的突变。分子分析是白血病诊断和临床管理的核心,可对临床和组织学印象进行基因确认,提供预后和预测信息,并有助于检测微小残留病。本单元将概述急性白血病和髓系肿瘤中最常见且与临床相关的基因改变的分子诊断方法。© 2017约翰威立国际出版公司